Sunday Aug 24
Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab...
Top-line results from nine ODYSSEY Phase 3 trials were announced in late ODYSSEY LONG-TERM - The 2,341-patient, double-blind trial is evaluating the long-term safety and efficacy of alirocumab versus placebo in combination with maximally tolerated lipid-lowering therapy, including statins, in patients with hypercholesterolemia who are at high ... (more)
IMPROVE-IT Trial Scheduled For Presentation In November
Results of the eagerly-awaited and highly controversial IMPROVE-IT trial are finally going to be revealed.
Medical News Today
Sanofi and Regeneron report positive top-line results from nine phase ...
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that nine new Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared to placebo or active comparator.
Positive Results Reported From Nine Phase III Trials of Alirocumab in Hypercholesterolemia
Nine new phase III studies of alirocumab in patients with hypercholesterolemia met their primary efficacy endpoint of a greater percent reduction from baseline in low-density lipoprotein cholesterol at 24 weeks compared with placebo or an active comparator.
Merck second-quarter profit more than doubles, tops forecast
A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.